Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AP1/21 - Antithrombotic Agents

Deadline: 02.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value (k = 2)	

Test [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}		AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
Set 1														
(108) Apixaban [µg/L]				32								32	28	88%
—— Samples and groups ——														
Sample A1	65,3	11	16	32		CVP	65,3	4,6	32%	44,4	86,2	32	28	88%
(2) Chromogenous substrat	65,3	11	16	32	0							32		
Sample B1	272	25	9,3	32		CVP	272	11	25%	204	340	32	32	100%
(2) Chromogenous substrat	272	25	9,3	32	0							32		
Set 2														
(109) Dabigatran [µg/L]				33								33	31	94%
—— Samples and groups ——														
Sample A2	51,5	8,5	16	33		CVP	51,5	3,6	32%	35	68	33	31	94%
(1) Coagulometer	52,4	9,8	19	25	0							25		
(2) Chromogenous substrat	50,5	3,7	7,3	8	0							8		
Sample B2	215	26	12	33		CVP	215	11	25%	161	269	33	33	100%
(1) Coagulometer	222	30	13	25	0							25		
(2) Chromogenous substrat	196	8,9	4,5	8	0							8		
Set 3														
(110) Rivaroxaban [µg/L]				38								38	36	95%
—— Samples and groups ——														
Sample A3	72,9	7,7	11	38		CVP	72,9	3,0	25%	54,6	91,2	38	36	95%
(2) Chromogenous substrat	72,9	7,7	11	38	0							38		
Sample B3	311	24	7,9	38		CVP	311	9,7	25%	233	389	38	38	100%
(2) Chromogenous substrat	311	24	7,9	38	0							38		

End of report

Printed: 09.04.2021